Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.
The treatment landscape for patients with multiple myeloma (MM) is constantly evolving. Over the past decade, the introduction of novel agents such as proteasome inhibitors and immunomodulatory drugs has led to notable changes in therapeutic strategy, and improvements in survival, yet MM remains incurable in the vast majority of cases. More recently, a targeted approach to MM treatment has emerged, using monoclonal antibodies (mAbs) to target antigens expressed on the surface of MM cells. MAbs tested to date kill MM cells via the host's immune system and/or by promoting apoptosis, and appear to have generally improved tolerability compared with currently available treatments. Due to their distinct mode of action, mAbs are promising both for patients who have exhausted current regimens, and as part of first-line treatments in newly diagnosed patients. This review examines the recent developments in mAb-based therapy for MM, primarily focused on those agents in ongoing clinical testing.
Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
S
S
Lonial
Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA.
B
B
Durie
Department of Hematology, University of Torino, Torino, Italy.
A
A
Palumbo
Clínica Universidad de Navarra, Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.
J
J
San-Miguel
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000235:genetics / Q000276:immunology; D017209:Apoptosis / Q000187:drug effects; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D018572:Disease-Free Survival; D015870:Gene Expression; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy / Q000639:trends*; D015850:Interleukin-6 / Q000235:genetics / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D010950:Plasma Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D061988:Proteasome Inhibitors / Q000627:therapeutic use; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D000071176:Signaling Lymphocytic Activation Molecule Family; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D053264:B-Cell Activating Factor; D007155:Immunologic Factors; D015850:Interleukin-6; D061988:Proteasome Inhibitors; D019718:Receptors, CXCR4; D011971:Receptors, Immunologic; D000071176:Signaling Lymphocytic Activation Molecule Family; D000093242:Interleukin-6 Inhibitors; C527276:CXCR4 protein, human; C508600:IL6 protein, human; C448987:SLAMF7 protein, human; C505719:TNFSF13B protein, human